Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of Rina-S with or without bevacizumab versus platinum-based chemotherapy with or without bevacizumab in recurrent platinum-sensitive ovarian cancer
jRCT2021260025Phase 3Recruiting
- Sponsor
- Genmab
- Start
- Aug 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of rinatabart sesutecan, bevacizumab, carboplatin, gemcitabine, paclitaxel and 1 more in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Genmab. Primary endpoint: Progression-free Survival. Started Aug 2026; status: recruiting.
02
Drugs
rinatabart sesutecanbevacizumabcarboplatingemcitabinepaclitaxel
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on jRCT2021260025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021260025.